cas 887581-47-7|| where to buy 6-chloro-3-(propan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione

Produktname:6-chloro-3-(propan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione

IUPAC Name:6-chloro-3-(propan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM467305-100mg	in stock	Ōƿƿ
CM467305-250mg	in stock	ŤľǸ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 887581-47-7 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:887581-47-7; Molekulare Formel:C7H9ClN2O2; Schmelzpunkt:-; SMILES-Code:CC(C)N1C(=O)NC(Cl)=CC1=O; Dichte:

: Katalognummer:CM467305; Molekulargewicht:188.61; Siedepunkt:; Mdl-Nr.:MFCD03001443; Lagerung:

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Mavacamten; CAMZYOS(Mavacamten) was recently approved in the European Union, following its approval in the U.S. and other markets worldwide, and is the first and only cardiac myosin inhibitor approved to treat adult patients with symptomatic obstructive hypertrophic cardiomyopathy(HCM).
Mavacamten is a first-in-class, targeted inhibitor of cardiac myosin, reduces the number of myosin-actin cross-bridges and thus decreases excessive contractility characteristic of HCM.